Bonacard

It is used in ischemic heart disease and clinical situations in which inhibition of platelet aggregation is targeted.

Type and content of packaging

PVC/PVDC/Aluminum blister contains 10 or 15 enteral tablets. In package: 15, 30, 60, 90, 120 enteral tablets. Commercial packaging is a cardboard box containing a patient leaflet and a blister with the corresponding number of tablets.

Pharmaceutical form

Enteral tablet. Round tablets, white to cream color, convex on both sides, 8 mm in diameter.

Dosage and administration

Oral administration. The enteral tablet has a special coating that prevents disintegration in the stomach, protecting against the irritating effect of acetylsalicylic acid on the gastric mucosa. The most common use is 1 tablet of 150 mg per day during or after a meal. Tablets should be swallowed whole with a drink of water.

Indications

• prevention of myocardial infarction in high-risk individuals,
• fresh myocardial infarction or suspected fresh myocardial infarction,
• unstable coronary artery disease,
• secondary prevention in post-myocardial infarction patients,
• condition after coronary artery bypass grafting, coronary angioplasty,
• prevention of transient cerebral ischemia (TIA) attacks and ischemic stroke in patients with TIA,
• after ischemic stroke in patients with TIA,
• in patients with peripheral arteriosclerosis,
• prevention of coronary thrombosis in patients with multiple risk factors,
• prevention of venous thrombosis and pulmonary embolism in patients with prolonged immobilization, such as after major surgery, as an adjunct to other means of prophylaxis.

Contraindications

Bonacard product should not be used:
• in case of hypersensitivity to the active substance acetylsalicylic acid, other salicylates or to any of the excipients listed in section 6.1,
• In patients with hemorrhagic diathesis,
• in patients with active gastric and/or duodenal ulcer disease,
• in patients with severe hepatic insufficiency,
• in patients with severe heart failure,
• in patients with a history of attacks of so-called aspirin asthma, induced by the administration of salicylates or substances with similar effects, especially non-steroidal anti-inflammatory drugs,
• concomitantly with methotrexate at doses of 15 mg per week or more (see section 4.5),
• in the last trimester of pregnancy,
• in children under 12 years of age in the course of viral infections due to the risk of Reye's syndrome, a rare but severe disease causing liver and brain damage.

Special precautions during storage

Store at temperatures below 25°C